Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
European Journal of Cancer2019Vol. 123, pp. 36–47
Citations Over TimeTop 10% of 2019 papers
Martin Förster, Magnus T. Dillon, Judit Kocsis, Éva Remenár, Gábor Pajkos, Frédéric Rolland, Jonathan Greenberg, Kevin J. Harrington
Related Papers
- → Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab(2016)44 cited
- → Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer(2022)38 cited
- → Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies(2019)6 cited
- → Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck(2009)5 cited
- → Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab(2016)2 cited